Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2016
At a glance
- Drugs Alisertib (Primary) ; Irinotecan
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- 20 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
- 16 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.